While ImClone Inc.'s former CEO Samuel Waksal waits to be sentenced on a series of fraud and other charges this week, the company he co-founded is pulling together a regulatory application on the long-awaited colorectal cancer drug Erbitux. (BioWorld Today)

While ImClone Inc.'s former CEO Samuel Waksal waits to be sentenced on a series of fraud and other charges this week, the company he co-founded is pulling together a regulatory application on the long-awaited colorectal cancer drug Erbitux. (BioWorld Today)